What is Molecule?
Molecule operates as a decentralized platform designed to expedite pharmaceutical innovation. By establishing an open market, the company connects scientists, patients, and industry stakeholders to foster collaborative research and development of pharmaceutical intellectual property. The Molecule protocol facilitates the distribution of ownership, risk, and costs associated with drug development, thereby creating novel innovation and business models aimed at delivering a broader range of inclusive treatments to patients. This approach allows IP creators to exchange partial ownership for enhanced access to liquidity, research resources, and funding.
How much funding has Molecule raised?
Molecule has raised a total of $13M across 1 funding round:
Angel/Seed
$13M
Angel/Seed (2022): $13M with participation from Backed, Shine Capital, Northpond Ventures, and Speedinvest
Key Investors in Molecule
Backed
Backed is a human-centric seed fund focused on supporting brave founders building generation-defining companies in frontier technology, with an average ticket size of $500K to $5M.
Shine Capital
Shine Capital is an early-stage venture capital firm that collaborates with innovative and determined entrepreneurs to create iconic businesses, focusing on partnering with individuals who demonstrate creativity and conviction.
Northpond Ventures
Northpond Ventures is dedicated to advancing science and technology to create significant impacts on humanity, focusing on identifying and supporting breakthrough innovations and entrepreneurial ventures.
What's next for Molecule?
The substantial enterprise-level funding positions Molecule for significant expansion and further development of its open market protocol. This strategic investment is expected to fuel advancements in distributed research and development, enabling the company to onboard more IP creators and accelerate the journey of diverse treatments from concept to patient. Molecule's focus on distributing ownership and risk is poised to reshape traditional drug development paradigms, potentially leading to a more inclusive and efficient pharmaceutical innovation ecosystem.
See full Molecule company page
